A human cancer-predisposing polymorphism in Cdc25A is embryonic lethal in the mouse and promotes ASK-1 mediated apoptosis

Springer Science and Business Media LLC - Tập 6 - Trang 1-9 - 2011
El Mustapha Bahassi1, Moying Yin2, Susan B Robbins2, Ya-Qin Li2, Deborah G Conrady2, Zhenyu Yuan2, Rhett A Kovall2, Andrew B Herr2, Peter J Stambrook2
1Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, USA
2Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, USA

Tóm tắt

Failure to regulate the levels of Cdc25A phosphatase during the cell cycle or during a checkpoint response causes bypass of DNA damage and replication checkpoints resulting in genomic instability and cancer. During G1 and S and in cellular response to DNA damage, Cdc25A is targeted for degradation through the Skp1-cullin-β-TrCP (SCFβ-TrCP) complex. This complex binds to the Cdc25A DSG motif which contains serine residues at positions 82 and 88. Phosphorylation of one or both residues is necessary for the binding and degradation to occur. We now show that mutation of serine 88 to phenylalanine, which is a cancer-predisposing polymorphic variant in humans, leads to early embryonic lethality in mice. The mutant protein retains its phosphatase activity both in vitro and in cultured cells. It fails to interact with the apoptosis signal-regulating kinase 1 (ASK1), however, and therefore does not suppress ASK1-mediated apoptosis. These data suggest that the DSG motif, in addition to its function in Cdc25A-mediated degradation, plays a role in cell survival during early embyogenesis through suppression of ASK1-mediated apoptosis.

Tài liệu tham khảo

Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 2000, 408: 433–439. 10.1038/35044005 Giaccia AJ, Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998, 12: 2973–2983. 10.1101/gad.12.19.2973 Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF: Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep 2000, 1: 71–79. 10.1093/embo-reports/kvd018 Zhao H, Watkins JL, Piwnica-Worms H: Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 2002, 99: 14795–14800. 10.1073/pnas.182557299 Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, Lukas J: Rapid destruction of human Cdc25A in response to DNA damage. Science 2000, 288: 1425–1429. 10.1126/science.288.5470.1425 Bernardi R, Liebermann DA, Hoffman B: Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 2000, 19: 2447–2454. 10.1038/sj.onc.1203564 Boutros R, Dozier C, Ducommun B: The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 2006, 18: 185–191. 10.1016/j.ceb.2006.02.003 Busino L, Chiesa M, Draetta GF, Donzelli M: Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 2004, 23: 2050–2056. 10.1038/sj.onc.1207394 Chen MS, Ryan CE, Piwnica-Worms H: Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14–3-3 binding. Mol Cell Biol 2003, 23: 7488–7497. 10.1128/MCB.23.21.7488-7497.2003 Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF: Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003, 426: 87–91. 10.1038/nature02082 Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF: Dual mode of degradation of Cdc25 A phosphatase. EMBO J 2002, 21: 4875–4884. 10.1093/emboj/cdf491 Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ, Harper JW: SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003, 17: 3062–3074. 10.1101/gad.1157503 Ray D, Terao Y, Nimbalkar D, Chu LH, Donzelli M, Tsutsui T, Zou X, Ghosh AK, Varga J, Draetta GF, Kiyokawa H: Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 2005, 25: 3338–3347. 10.1128/MCB.25.8.3338-3347.2005 Bartek J, Lukas J: Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001, 490: 117–122. 10.1016/S0014-5793(01)02114-7 Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410: 842–847. 10.1038/35071124 Kristjansdottir K, Rudolph J: Cdc25 phosphatases and cancer. Chem Biol 2004, 11: 1043–1051. 10.1016/j.chembiol.2004.07.007 Blomberg I, Hoffmann I: Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol Cell Biol 1999, 19: 6183–6194. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, Piwnica-Worms H: GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008, 13: 36–47. 10.1016/j.ccr.2007.12.002 Melixetian M, Klein DK, Sorensen CS, Helin K: NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint. Nat Cell Biol 2009, 11: 1247–1253. 10.1038/ncb1969 Isoda M, Kanemori Y, Nakajo N, Uchida S, Yamashita K, Ueno H, Sagata N: The extracellular signal-regulated kinase-mitogen-activated protein kinase pathway phosphorylates and targets Cdc25A for SCF beta-TrCP-dependent degradation for cell cycle arrest. Mol Biol Cell 2009, 20: 2186–2195. 10.1091/mbc.E09-01-0008 NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department of Genome Sciences, Seattle, WA, Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases [http://egp.gs.washington.edu] Karagoz ID, Ozaslan M, Cengiz B, Kalender ME, Kilic IH, Oztuzcu S, Gogebakan B, Demiryurek AT: CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma. Tumour Biol 2010, 31: 597–604. 10.1007/s13277-010-0075-z Clucas C, Cabello J, Bussing I, Schnabel R, Johnstone IL: Oncogenic potential of a C. elegans cdc25 gene is demonstrated by a gain-of-function allele. EMBO J 2002, 21: 665–674. 10.1093/emboj/21.4.665 Zou X, Tsutsui T, Ray D, Blomquist JF, Ichijo H, Ucker DS, Kiyokawa H: The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol Cell Biol 2001, 21: 4818–4828. 10.1128/MCB.21.14.4818-4828.2001 Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson EC, Zou X, Franks R, Christov K, Kiyokawa H: Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 2007, 67: 6605–6611. 10.1158/0008-5472.CAN-06-4815 Galaktionov K, Chen X, Beach D: Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996, 382: 511–517. 10.1038/382511a0 Fuhrmann G, Leisser C, Rosenberger G, Grusch M, Huettenbrenner S, Halama T, Mosberger I, Sasgary S, Cerni C, Krupitza G: Cdc25A phosphatase suppresses apoptosis induced by serum deprivation. Oncogene 2001, 20: 4542–4553. 10.1038/sj.onc.1204499 Wells PG, McCallum GP, Chen CS, Henderson JT, Lee CJ, Perstin J, Preston TJ, Wiley MJ, Wong AW: Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol Sci 2009, 108: 4–18. 10.1093/toxsci/kfn263 Laue TM, Shah BD, Ridgeway TM, Pelletier SM: Computer-aided interpretation of analytical sedimentation data for proteins. In Analytical Ultracentrifugation in Biochemistry and Polymer Science. Edited by: Harding SE, Rowe AJ, Hornton JC. Cambridge: Royal Society of Chemistry; 1992:90–125. Johnson WC: Analyzing protein circular dichroism spectra for accurate secondary structures. Proteins 1999, 35: 307–312. 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3 Whitmore L, Wallace BA: DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 2004, 32: W668–673. 10.1093/nar/gkh371 Baratte B, Meijer L, Galaktionov K, Beach D: Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. Anticancer Res 1992, 12: 873–880.